Key Takeaways
- • OrbiMed has raised US$3bn in commitments across two new private equity funds, OrbiMed Private Investments X and OrbiMed Asia Partners VI, according to the firm's press release.
- • OrbiMed Private Investments X raised over US$1.9bn to invest in US and European life sciences venture capital opportunities.
- • OrbiMed Asia Partners VI raised over US$1bn for healthcare growth equity and venture capital investments across Asia.
- • Both funds target biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services, with LPs including medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.
- • OrbiMed manages more than US$21bn in assets globally across private equity, public equity and royalty/credit strategies.
Summary
OrbiMed, a US-based global healthcare investment firm, has raised US$3bn in commitments across two new private equity funds, according to a press release reported by Investors in Healthcare. The capital is split between OrbiMed Private Investments X, which raised over US$1.9bn to invest in US and European life sciences venture capital opportunities, and OrbiMed Asia Partners VI, which raised over US$1bn for healthcare growth equity and venture capital investments across Asia. Both vehicles target biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services.
Investors in the new funds include medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices. The article does not disclose individual commitment sizes or a final close date.
Carl Gordon, a managing partner of OrbiMed, said there has never been a more exciting time to invest in life sciences innovation. He cited artificial intelligence, a proliferation of new therapeutic modalities and China's emergence as a biotechnology powerhouse as factors expanding the opportunity set for developing transformative treatments.
OrbiMed manages more than US$21bn in assets globally, investing across the healthcare industry from start-ups to large multinational companies through private equity, public equity and royalty/credit funds.
Investors in the new funds include medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices. The article does not disclose individual commitment sizes or a final close date.
Carl Gordon, a managing partner of OrbiMed, said there has never been a more exciting time to invest in life sciences innovation. He cited artificial intelligence, a proliferation of new therapeutic modalities and China's emergence as a biotechnology powerhouse as factors expanding the opportunity set for developing transformative treatments.
OrbiMed manages more than US$21bn in assets globally, investing across the healthcare industry from start-ups to large multinational companies through private equity, public equity and royalty/credit funds.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.